Wolverine Asset Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Wolverine Asset Management’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-20	Closed	-$3K	–	1693
2015 Q3	$3K	Sell	20 -210	-91%	-$2.8K	﹤0.01%	1686
2015 Q2	$3K	Buy	230 +216	+1,543%	+$2.46K	﹤0.01%	1713
2015 Q1	$3K	Hold	14	–	–	﹤0.01%	1674
2014 Q4	$3K	Sell	14 -261	-95%	-$2.88K	﹤0.01%	1912
2014 Q3	$101K	Hold	275	–	–	﹤0.01%	1297
2014 Q2	$100K	Buy	+275	New	+$2.68K	﹤0.01%	1147

Other funds holding BCRX

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

VMI

VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Wolverine Asset Management's BCRX Position: Q1 2016 in Review

Wolverine Asset Management sold out of BioCryst Pharmaceuticals (BCRX) in Q1 2016, closing a stake of 5,100 shares — an estimated $52K sold.

Wolverine Asset Management first reported a position in BCRX in Q2 2014 and held it in 5 quarters. The position peaked at $107K in Q2 2015. 109 funds tracked by Wall St. Rank hold BCRX as of Q1 2016.

Wolverine Asset Management reported no remaining BioCryst Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
Wolverine Asset Management sold 5,100 BioCryst Pharmaceuticals shares in Q1 2016, an estimated $52K.
Wolverine Asset Management first reported a position in BioCryst Pharmaceuticals in Q2 2014 and held it in 5 quarters.
Wolverine Asset Management's BioCryst Pharmaceuticals position peaked at $107K in Q2 2015.
109 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2016.

Based on Wolverine Asset Management's 13F filing for Q1 2016, filed 16 May 2016.